Five-treatment radiation regimen poised to become standard of care, phase III data show

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Men with intermediate-risk prostate cancer can receive a complete course of radiation in just five treatments—rather than the typical 20 to 28—while maintaining excellent cancer control and improving quality of life, according to results of an international phase III trial conducted by Rodney J. Ellis. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Positive high-level results from the Tropion-Breast02 phase III trial showed Datroway (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival compared to investigator’s choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login